Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Children with low-risk retinoblastoma do not need postoperative chemotherapy

Children with low-risk retinoblastoma do not need postoperative chemotherapy

Two-step personalized immunotherapy safe for patients with ovarian cancer

Two-step personalized immunotherapy safe for patients with ovarian cancer

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Immunosuppressive drugs do not increase risk of cancer in lupus patients

Immunosuppressive drugs do not increase risk of cancer in lupus patients

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Ibrutinib may effectively combat chronic lymphocytic leukemia

Ibrutinib may effectively combat chronic lymphocytic leukemia

Study provides important data about fertility window of women with childhood cancer

Study provides important data about fertility window of women with childhood cancer

Rethinking therapy decisions in autoimmune encephalopathy

Rethinking therapy decisions in autoimmune encephalopathy

Certain patients with prostate cancer may benefit from Provenge clinical trial

Certain patients with prostate cancer may benefit from Provenge clinical trial

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Canine lymphoma treatment adds up to cystitis

Canine lymphoma treatment adds up to cystitis

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

New findings on how OX40 activation affects T helper cells that target melanoma

New findings on how OX40 activation affects T helper cells that target melanoma

Computed tomography aids scleroderma lung disease prognosis

Computed tomography aids scleroderma lung disease prognosis

Assisted reproduction technology may increase risk of MS activity among women

Assisted reproduction technology may increase risk of MS activity among women

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Bone marrow transplants hold promise for sickle cell patients

Bone marrow transplants hold promise for sickle cell patients

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients